PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcurolBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Urology
 
BMC Urol. 2012; 12: 3.
Published online Feb 22, 2012. doi:  10.1186/1471-2490-12-3
PMCID: PMC3305626
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Kazuhiko Nakano,corresponding author1 Shigeyuki Ohta,1 Kenji Komatsu,1 Taro Kubo,1 Akinori Nukui,1 Kazumi Suzuki,1 Shinsuke Kurokawa,1 Minoru Kobayashi,1 and Tatsuo Morita1
1Department of Urology, Jichi Medical University, Yakushiji 3311-1, Shimotsuke-city, Tochigi 3290498, Japan
corresponding authorCorresponding author.
Kazuhiko Nakano: nknkzhk/at/jichi.ac.jp; Shigeyuki Ohta: tsutsuji/at/jichi.ac.jp; Kenji Komatsu: komatsu/at/jichi.ac.jp; Taro Kubo: t.kubo/at/jichi.ac.jp; Akinori Nukui: nukui/at/jichi.ac.jp; Kazumi Suzuki: s.kazu/at/jichi.ac.jp; Shinsuke Kurokawa: s-kuro/at/jichi.ac.jp; Minoru Kobayashi: minoruk/at/jichi.ac.jp; Tatsuo Morita: moritatu/at/jichi.ac.jp
Received October 9, 2011; Accepted February 22, 2012.
Abstract
Background
The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the significance of DTX and EMP combination therapy in Japanese EMP-refractory CRPC patients.
Methods
To compare the efficacy and toxicity of DTX and EMP, we divided CRPC patients, who were confirmed to be resistant to EMP, into the following two groups: group D (n = 28), which included patients treated with DTX (60 mg/m2, once in every four weeks) alone, and group DE (n = 33), which included patients treated with a combination of DTX (60 mg/m2, once in every four weeks) and EMP (twice daily oral administration at 280 mg).
Results
Prostate specific antigen (PSA) response (> 50% decline in PSA) was observed in six patients (21%) in group D and eight patients (24%) in group DE. The median time to progression (TTP) was 12.0 months and 6.2 months and the median overall survival (OS) was 26.4 months and 24.3 months in group D and DE, respectively. There was no statistical difference between the two groups in terms of PSA response, TTP, and OS. The incidence of adverse events of grade 3/4 was low in both the groups, and there was no statistical difference between the two groups.
Conclusions
Although treatment with DTX at 60 mg/m2 was effective and highly tolerated in EMP-refractory Japanese CRPC patients, the DTX and EMP combination therapy might not exhibit any survival benefit for CRPC patients.
Articles from BMC Urology are provided here courtesy of
BioMed Central